Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
about
Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsPulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled TrialsTargeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunitiesMethodological issues in observational studies and non-randomized controlled trials in oncology in the era of big data.Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosisHigh-resolution CT of complications of idiopathic fibrotic lung diseaseIncreased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis.Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patientsEffect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung disease: an association study.Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancerEGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium.Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung diseaseInterstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.State-of-the-art MS technology applications in lung disease.Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registryDrug induced interstitial lung disease.Fatal interstitial lung disease associated with icotinibTargeting precision medicine toxicity: recent developments.Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis.Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung CancerThe Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary DiseasesRe-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literatureGefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 CellsImpact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer.Tyrosine kinase inhibitors in lung cancer.Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer.Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer.First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance studyOptimizing response to gefitinib in the treatment of non-small-cell lung cancer.Review of the treatment of non-small cell lung cancer with gefitinib.The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology
P2860
Q26750428-C6E195AA-C0DD-4FDC-A4DB-CF8AB4A76130Q26768125-4C0194F6-61CE-4B49-91EE-4B3560516C54Q27027433-F10A4D96-8BCC-4B93-BAD5-F268565A968CQ27691076-60CEA8F9-47B4-48C4-AE5F-7BE70320309EQ28477887-0E797A12-571A-4654-9FFA-1A6018389B45Q30462254-8D89B7F8-CCA0-4941-895D-7210890B75EBQ30540860-D7EFFD3C-4F19-4C94-B791-C475251EC5B2Q31026775-5E54DDB9-BF96-4DCD-A28F-DE8CAE781D5FQ33399107-D116CE53-AB82-446F-83B1-C3C27674239BQ33408049-B6446B75-F9AD-4D28-A3E7-FD73A9407AE3Q33424081-4A6B1690-EB38-4E82-93D7-1A974080CCE4Q33490820-1813E761-E86E-4313-86D9-92B2549CDD47Q33600748-8B3F14EC-2595-406C-8FE9-957481E69659Q33710152-C1000A3A-7749-4FD8-9DDD-A57AFC517E83Q33714029-79E52B2C-08B2-4EBC-84FA-672B796A87B9Q33938475-ABB7724E-12C1-4D72-A154-4A48DC810444Q33970386-CF32C171-CB60-4DD0-A74B-F5CE6E714E8CQ34089332-649E554F-9ED5-4379-8EB2-5546B2D8A4C4Q34426450-1EC41A33-3F1C-4129-9120-D1AD3747B8E5Q34641494-09DBCC68-FBED-4E5B-9503-1DFD845729A9Q34814528-6B401F69-242A-4AC3-A7EB-AF95DA21893AQ35019470-AF46FC03-AFBA-4E75-9047-27E2639AA84AQ35052012-05D2B03D-3238-4070-9060-1ED4C58D39BCQ35168112-2A0F8350-E018-4777-AC7D-DADC954678ACQ35179046-CAE6FDEB-A971-4628-B5CC-66B7C2D6F03CQ35179355-242D9F6E-AAC0-4E90-87B5-99F2E835FA19Q35608002-C5954662-0C1D-4DB4-B5AC-F1E01250C6CFQ35608617-CAE98700-5B7F-4F4D-8EC0-D1DE1B65A6CDQ35742303-296497E8-F4E4-4879-A046-B8C33BF1B6FFQ35750388-C49FDB6F-EF1E-41FB-9C2B-3C9C18147680Q35804538-834B9CFF-7EAE-4C01-9204-858C3E3A0EB5Q35908430-7E576C86-9B7C-473C-890B-1203C3B4A8F4Q35999625-D584489C-27D0-42B7-89DA-585CC966413FQ36224203-5F732BD9-68DC-4EA9-9514-4F45A9FC9805Q36231697-8823E51D-90A4-4134-AFA4-31A59711ADBEQ36283596-994FD0D1-C1F0-43EF-9128-B6AA7E79444EQ36337416-121FC184-189E-49F3-AF69-414EF48C043CQ36441490-837997EE-FD0B-4B40-A899-333FCE18F37DQ36461805-A71A39A1-6FFB-4670-81C7-FCE5DB73B14FQ36463971-71E8C0E6-D6F3-4A1E-AAD5-477C3C62AD12
P2860
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Interstitial lung disease in J ...... and nested case-control study.
@en
Interstitial lung disease in J ...... and nested case-control study.
@nl
type
label
Interstitial lung disease in J ...... and nested case-control study.
@en
Interstitial lung disease in J ...... and nested case-control study.
@nl
prefLabel
Interstitial lung disease in J ...... and nested case-control study.
@en
Interstitial lung disease in J ...... and nested case-control study.
@nl
P2093
P2860
P1476
Interstitial lung disease in J ...... and nested case-control study.
@en
P2093
Alison Armour
Claire Watkins
Fredrik Nyberg
Haiyi Jiang
Harubumi Kato
Japan Thoracic Radiology Group
Kazuhiko Nakagawa
Kouichiro Nakata
Masahiro Fukuoka
Masahiro Tsuboi
P2860
P304
P356
10.1164/RCCM.200710-1501OC
P407
P577
2008-03-12T00:00:00Z